United Therapeutics Corporation (UTHR)
UTHR moved a median of +0.03% 30 minutes after news, and +0.03% by the close. How UTHR actually reacts to news — the realized, point-in-time move the market made, measured across 964 labeled events over the last three years with zero look-ahead.
UTHR’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.02% | 45% | 958 |
| 30-min | +0.03% | 52% | 962 |
| 60-min | +0.06% | 53% | 962 |
| to close | +0.03% | 51% | 958 |
| Middle 50% of UTHR reactions | -0.52% to +0.58% |
|---|---|
| Median reaction (30-min) | +0.03% |
| Measured reactions | 964 |
Half of all United Therapeutics Corporation news events land between -0.52% and +0.58% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How UTHR reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 26 | +0.08% | 54% | -0.46% |
| Analyst downgrades | 22 | -0.12% | 46% | +0.01% |
| Coverage initiations | 16 | -0.33% | 38% | -0.63% |
| Rating reiterations | 95 | +0.14% | 61% | +0.27% |
| Price-target raises | 41 | +0.02% | 54% | +0.10% |
| Price-target cuts | 11 | 0.00% | 46% | -0.31% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. See how UTHR ranks against every other measured name →
That’s how UTHR usually reacts — get an email when it moves on news →Email me when UTHR moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to UTHR's baseline. Nothing else.
Recent UTHR events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K UNITED THERAPEUTICS Corp For: Oct 13 | SEC filing · Form 8-K | SEC EDGAR | -1.00% | -0.58% | |
| United Therapeutics Presents New Data at the CHEST 2026 Annual Meeting | Press release | Business Wire | -0.16% | -1.49% | |
| United Therapeutics Corporation Prevails in Patent Litigation Against Liquidia | Press release | Business Wire | +0.95% | +2.48% | |
| Form 8-K UNITED THERAPEUTICS Corp For: Sep 08 | SEC filing · Form 8-K | SEC EDGAR | -0.36% | +1.78% | |
| United Therapeutics Corporation Announces Accelerated Share Repurchase Agreement for Remainder of $2.0 Billion Authorization | Press release | Business Wire | -0.98% | +0.91% | |
| United Therapeutics Corporation Announces FDA Acceptance of Supplemental New Drug Application for Nebulized Tyvaso® to Treat Idiopathic Pulmonary Fibrosis | Press release | Business Wire | -1.27% | -3.52% | |
| United Therapeutics Corporation Announces Participation at Upcoming Investor Conferences | Press release | Business Wire | +0.21% | -0.29% | |
| United Therapeutics Presents Data at The European Society of Cardiology Congress 2026 and The European Respiratory Society International Congress 2026 | Press release | Business Wire | -0.59% | -1.96% | |
| United Therapeutics Corporation Announces FDA Filing Acceptance of New Drug Application for Ralinepag to Treat Pulmonary Arterial Hypertension | Press release | Business Wire | -0.25% | -0.05% | |
| United Therapeutics Corporation Announces Full Enrollment of the TETON-PPF Study of Inhaled Treprostinil for the Treatment of Progressive Pulmonary Fibrosis | Press release | Business Wire | +0.61% | +1.23% | |
| Form 10-Q UNITED THERAPEUTICS Corp For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.06% | +2.77% | |
| Form 8-K UNITED THERAPEUTICS Corp For: Aug 05 | SEC filing · Form 8-K | SEC EDGAR | -0.06% | +2.77% | |
| United Therapeutics Corporation Reports Second Quarter 2026 Financial Results | Press release | Business Wire | -0.06% | +2.77% | |
| United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Published in The Lancet | Press release | Business Wire | -0.28% | -0.26% | |
| Form 8-K UNITED THERAPEUTICS Corp For: Jul 22 | SEC filing · Form 8-K | SEC EDGAR | +0.87% | +1.20% | |
| United Therapeutics Corporation Announces Appointment of Victor Dzau to its Board of Directors | Press release | Business Wire | +0.87% | +1.20% | |
| United Therapeutics Corporation to Report Second Quarter 2026 Financial Results Before Market Open on Wednesday, August 5, 2026 | Press release | Business Wire | -0.24% | -1.64% | |
| Form S-8 UNITED THERAPEUTICS Corp | SEC filing · Form S-8 | SEC EDGAR | -1.11% | -1.09% | |
| Form S-8 POS UNITED THERAPEUTICS Corp | SEC filing · Form S-8 | SEC EDGAR | -1.11% | -1.09% | |
| United Therapeutics Corporation Acquires Thymmune Therapeutics | Press release | Business Wire | -0.67% | +0.23% | |
| Form 8-K UNITED THERAPEUTICS Corp For: Jun 26 | SEC filing · Form 8-K | SEC EDGAR | +0.03% | -1.02% | |
| United Therapeutics Corporation Announces FDA Approval of the LungFX™ Device for Centralized Ex Vivo Lung Perfusion | Press release | Business Wire | -0.75% | -0.12% | |
| Form SD UNITED THERAPEUTICS Corp | SEC filing · Form SD | SEC EDGAR | +0.03% | +1.10% | |
| United Therapeutics Corporation to Present at the Jefferies Global Healthcare Conference | Press release | Business Wire | -0.30% | -1.38% | |
| United Therapeutics Corporation Announces TETON-1 Study of Tyvaso Published in The New England Journal of Medicine and Presented at ATS 2026 | Press release | Business Wire | +0.18% | -0.03% | |
| United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Presented at ATS 2026 | Press release | Business Wire | -0.53% | -0.53% | |
| United Therapeutics Corporation Announces FDA Clearance to Proceed with UHeart Xenotransplantation Clinical Trial | Press release | Business Wire | -0.53% | -0.53% | |
| Varda Space Industries and United Therapeutics Collaborate to Advance Microgravity-Enabled Treatments for Rare Pulmonary Disease | Press release | PR Newswire | -0.75% | -0.28% | |
| United Therapeutics Corporation to Present at the RBC Capital Markets Global Healthcare Conference | Press release | Business Wire | +0.02% | +2.09% | |
| United Therapeutics Corporation Presents New Data from TETON-1, ADVANCE OUTCOMES, and Additional Research in Pulmonary Hypertension and Pulmonary Fibrosis at ATS 2026 | Press release | Business Wire | +1.20% | +0.52% | |
| Form 10-Q UNITED THERAPEUTICS Corp For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +3.05% | +1.24% | |
| Form 8-K UNITED THERAPEUTICS Corp For: May 06 | SEC filing · Form 8-K | SEC EDGAR | +3.05% | +1.24% | |
| United Therapeutics Corporation Reports First Quarter 2026 Financial Results | Press release | Business Wire | +3.05% | +1.24% | |
| Form ARS UNITED THERAPEUTICS Corp For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.63% | +1.12% | |
| Form DEF 14A UNITED THERAPEUTICS Corp For: Jun 26 | SEC filing · Form DEF | SEC EDGAR | +0.63% | +1.12% | |
| Form DEFA14A UNITED THERAPEUTICS Corp | SEC filing · Form DEFA14A | SEC EDGAR | +0.63% | +1.12% | |
| United Therapeutics Corporation Announces Retirement of Professor Raymond Dwek, C.B.E., F.R.S., From Its Board of Directors | Press release | Business Wire | +0.63% | +1.12% | |
| United Therapeutics Corporation to Report First Quarter 2026 Financial Results Before Market Open on Wednesday, May 6, 2026 | Press release | Business Wire | +0.34% | +0.11% | |
| United Therapeutics Corporation Presents New Data Spanning Pulmonary Hypertension Treatment, Lung Donor Expansion, and Xenotransplantation at ISHLT 2026 | Press release | Business Wire | -0.81% | -2.62% | |
| United Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for miroliverELAP® for Treatment of Acute Liver Failure | Press release | Business Wire | -1.11% | +1.74% | |
| Form 8-K UNITED THERAPEUTICS Corp For: Mar 30 | SEC filing · Form 8-K | SEC EDGAR | -1.62% | -2.69% | |
| United Therapeutics Corporation Announces TETON-1 Pivotal Study of Tyvaso® Meets Primary Endpoint for Treatment of Idiopathic Pulmonary Fibrosis, Exceeding Impressive Treatment Effect Seen in TETON-2 | Press release | Business Wire | -1.62% | -2.69% | |
| United Therapeutics Corporation Announces Full Results of TETON-2 Phase 3 Clinical Trial Published in The New England Journal of Medicine | Press release | Business Wire | -0.48% | -1.30% | |
| Form 8-K UNITED THERAPEUTICS Corp For: Mar 09 | SEC filing · Form 8-K | SEC EDGAR | +0.91% | +1.89% | |
| United Therapeutics Corporation Announces $2 Billion Stock Repurchase Authorization and Enters into $1.5 Billion Accelerated Share Repurchase Program | Press release | Business Wire | +2.70% | +6.31% | |
| United Therapeutics Corporation to Present at the Leerink Global Healthcare Conference | Press release | Business Wire | -1.00% | -2.07% | |
| Form 8-K UNITED THERAPEUTICS Corp For: Mar 02 | SEC filing · Form 8-K | SEC EDGAR | +1.89% | +0.84% | |
| United Therapeutics Corporation Announces Ralinepag Achieved 55% Reduction in Risk of Clinical Worsening in Pivotal Pulmonary Arterial Hypertension Study, Delivering Exceptional, Highly Statistically Significant Efficacy | Press release | Business Wire | +1.89% | +0.84% | |
| Form 10-K UNITED THERAPEUTICS Corp For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +3.92% | +11.48% | |
| Form 8-K UNITED THERAPEUTICS Corp For: Feb 25 | SEC filing · Form 8-K | SEC EDGAR | +3.92% | +11.48% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the UTHR section they belong to.
Where else UTHR is measured.
UTHR earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Recro Pharma, Inc. (REPH) | 965 | 0.00% | 43% |
| Athenex, Inc. (ATNX) | 964 | -0.43% | 41% |
| Natera, Inc. (NTRA) | 957 | +0.21% | 57% |
| Antares Pharma, Inc. (ATRS) | 951 | 0.00% | 43% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is United Therapeutics Corporation's median reaction calculated?
Every labeled UTHR news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 964 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 52% of UTHR's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does UTHR's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.